In the current study, dulaglutide, a long-acting GLP-1 agonist, exhibited potential therapeutic benefits for MS-induced T2DM and obesity by direct insulin-dependent effects that improve hyperglycemia and IR. Here, GCG is linked to myeloid sarcoma.